Neupath Health Inc.

As of June 30, 2026, Neupath Health Inc. carries a market capitalization of 37.04M, placing it among publicly traded companies globally. Its enterprise value stands at 47.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neupath Health Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Neupath Health Inc. has 56.98M shares outstanding.

As of June 30, 2026, Neupath Health Inc. trades at a trailing price-to-earnings ratio of 27.27. The price-to-sales ratio is 0.41, and the price-to-book ratio stands at 1.61.

As of June 30, 2026, Neupath Health Inc. trades at an EV/EBITDA multiple of 11.92 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 47.17M versus a market cap of 37.04M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Neupath Health Inc. maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 56.17, indicating elevated leverage, while an interest coverage ratio of 5.05 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Neupath Health Inc. posted a return on equity (ROE) of 6.06, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.97, measuring how efficiently the asset base is converted into earnings. The company generates approximately 421,668.25 in revenue per employee across its workforce of 211.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Neupath Health Inc. recorded an income tax benefit of -702,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 926,000.00, leaving 1.34M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Neupath Health Inc.'s stock has gained approximately 38.46% over the past 52 weeks. The 50-day moving average sits at 0.56, while the 200-day moving average is 0.55.

Over the twelve months ended June 30, 2026, Neupath Health Inc. generated 88.97M in revenue and converted that into 1.34M in net income, yielding earnings per share of 0.03. EBITDA reached 3.96M, while operating income came in at 2.39M.

As of June 30, 2026, Neupath Health Inc. holds 3.51M in cash and equivalents against 13.16M in total debt, resulting in a net debt position of 2.34M. Total book value stands at 22.94M, with working capital of 2.25M providing operational flexibility.

Neupath Health Inc. produced 3.41M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -996,000.00 in capital expenditures, free cash flow totaled 2.41M - equivalent to 0.04 per share.

Over the twelve months ended June 30, 2026, Neupath Health Inc. posted a gross margin of 18.70, reflecting its pricing power and cost economics. The operating margin of 2.68 and net profit margin of 1.51 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.33, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.02, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Neupath Health Inc. shareholders.

Neupath Health Inc.'s most recent stock split took place on July 6, 2020 with a 5:1 split ratio.

As of June 30, 2026, Neupath Health Inc. has an Altman Z-Score of 3.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.